This is a type of medicine called an immunotherapy drug. It helps your body's own immune system fight certain types of cancer, like melanoma and lung cancer. It works by blocking a signal that cancer cells use to hide from the immune system.
Every report comes from a Lived member, sent anonymously.
Have you tried Opdivo (Nivolumab) for Melanoma?
Nivolumab, sold as Opdivo, is a cancer immunotherapy. It is a lab-made antibody that helps the immune system recognize and attack cancer cells, and it belongs to a group of medicines called immune checkpoint inhibitors. It is always given by a care team at a clinic or infusion center. Opdivo is approved for many cancers in adults, including melanoma, non-small cell lung cancer, kidney cancer (renal cell carcinoma), classical Hodgkin lymphoma, squamous cell cancer of the head and neck, cancer of the bladder and urinary tract lining (urothelial carcinoma), liver cancer, pleural mesothelioma (a cancer of the lining around the lungs), and cancers of the esophagus and stomach. Some approvals also include young people 12 and older, for melanoma, Hodgkin lymphoma, and a type of colorectal cancer whose tumor tests show a feature called MSI-H or dMMR (microsatellite instability-high or mismatch repair deficient, meaning a defect in how cells repair their DNA). It is used at several points in cancer care: for cancer that has spread or cannot be removed with surgery; before surgery for some lung cancers; and after surgery to lower the chance that melanoma, urinary tract cancer, esophageal cancer or lung cancer comes back. Depending on the cancer, nivolumab is given alone or combined with chemotherapy, with ipilimumab (Yervoy, another immunotherapy), or with cabozantinib (Cabometyx, a daily targeted pill for kidney cancer). Many approvals depend on tumor test results, such as how much of a protein called PD-L1 the cancer makes, or whether a lung cancer carries an EGFR or ALK gene change that is better treated with targeted pills first. Two related products also contain nivolumab. Opdivo Qvantig is nivolumab combined with hyaluronidase, an enzyme that allows it to be given as a short injection under the skin; it is approved for many of the same uses but not in combination with ipilimumab. Opdualag combines nivolumab with relatlimab, a second immunotherapy, for advanced melanoma in people 12 and older. These products are dosed differently and are not substituted for one another.
T cells are immune cells that can find and destroy abnormal cells, including cancer cells. To keep them from attacking healthy tissue, T cells carry built-in brakes called checkpoints. One of these is a receptor called PD-1 (programmed death receptor-1). When PD-1 is engaged by partner proteins called PD-L1 and PD-L2, the T cell is held back. Some tumors make extra PD-L1, which lets them switch off the immune cells that would otherwise attack them. Nivolumab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. It binds to PD-1 and blocks those partner proteins from reaching it, releasing the brake so T cells can respond to the cancer again. Ipilimumab blocks a different checkpoint called CTLA-4, and using the two together activates T cells more strongly than either alone. That stronger effect is why the combination is used for some cancers, and also why it causes more immune side effects. Because nivolumab works through the immune system rather than by killing cells directly, its benefit can take time to show, and it does not work for everyone. The same released brake explains its distinctive risk: the immune system can also turn on healthy organs.
Opdivo is given as an intravenous (IV) infusion into a vein, usually over 30 minutes. Depending on the cancer and the treatment plan, it is given every 2, 3 or 4 weeks. Most adults receive a fixed dose; younger patients who weigh less than 40 kg (about 88 pounds) receive a dose based on body weight. When it is combined with chemotherapy or ipilimumab, those medicines are often given the same day, sometimes for a set number of cycles before nivolumab continues alone. Opdivo Qvantig is injected under the skin of the abdomen or thigh by a health professional, over 3 to 5 minutes. Its doses are different from IV nivolumab, so the two are not switched dose for dose. The dose of nivolumab is not lowered to manage side effects. Instead, the care team pauses or permanently stops treatment, depending on the type and severity of the reaction. How long treatment lasts depends on its purpose. After surgery, it is usually given for up to about a year. For advanced cancer, it generally continues as long as it is working and tolerated, and for many uses it stops after 2 years. If an appointment is missed, call the care team to reschedule rather than waiting for the next one.
The most common side effects of nivolumab alone are tiredness, rash, itching, muscle, bone and joint pain, diarrhea, nausea, cough, shortness of breath and decreased appetite. Many are mild. When nivolumab is combined with chemotherapy, ipilimumab or cabozantinib, the side effects of those medicines add to these, and immune side effects become more frequent with ipilimumab. The side effects that matter most are immune-related: inflammation of a healthy organ caused by the reactivated immune system. They can affect almost any part of the body, can occasionally become severe or fatal, and can start at any time, including months after the last dose. The thyroid is affected most often; about 8% of people taking nivolumab alone in clinical trials developed an underactive thyroid, which is treated with daily thyroid hormone and is often permanent. Lung inflammation (pneumonitis) occurred in about 3%. Others include inflammation of the colon (colitis), liver (hepatitis), kidneys and skin, and, less often, the pituitary or adrenal glands, which control key hormones. Nivolumab can also trigger type 1 diabetes, which is usually permanent and can first appear as diabetic ketoacidosis, a dangerous buildup of acids in the blood. Rarely, the heart, nerves, muscles or eyes are affected. Contact the care team right away for any new or worsening: cough, shortness of breath or chest pain; diarrhea, more frequent bowel movements, bloody or black stools, or severe stomach pain; yellowing of the skin or eyes, severe nausea or vomiting, pain on the right side of the abdomen, or easier bruising or bleeding; rash, blistering or peeling skin, or mouth sores; much less urine, blood in the urine or ankle swelling; headaches that will not go away, extreme tiredness, dizziness or fainting, or unusual hunger, thirst or urination; and confusion, a stiff neck, numbness, severe muscle weakness, eye pain or vision changes. Most immune reactions are treated by pausing nivolumab and giving corticosteroids such as prednisone, or hormone replacement when a gland stops working. Treatment started early can help keep a reaction from becoming more serious. Reactions during the infusion, such as chills, flushing, itching, fever, wheezing or feeling faint, are uncommon and are handled by the infusion staff; tell the nurse right away if they happen.
Nivolumab has no absolute contraindications, but some medical histories change the balance of risk and benefit. Tell the care team beforehand about an autoimmune disease such as Crohn's disease, ulcerative colitis or lupus, since the treatment works by releasing the immune system's brakes and key studies excluded people with autoimmune disease. The same applies to any organ or tissue transplant, including a cornea, because nivolumab can trigger rejection, and to a nervous system condition such as myasthenia gravis or Guillain-Barré syndrome. Past radiation to the chest raises the chance of lung inflammation with this type of medicine. People who have had, or may later need, a stem cell transplant from a donor (allogeneic transplant) face a risk of serious and sometimes fatal transplant complications, so the timing needs careful planning with both teams. The label does not list specific drug interactions, but the care team should know about every medicine and supplement, especially corticosteroids or other drugs that suppress the immune system. When nivolumab is given with chemotherapy, ipilimumab or cabozantinib, each of those medicines brings its own interactions and warnings. Nivolumab can harm a developing baby. A pregnancy test is advised before starting for people who could become pregnant, along with effective birth control during treatment and for at least 5 months after the last dose. Breastfeeding is not recommended during treatment or for 5 months afterward.
Each visit usually includes a check-in and blood tests before the dose. Liver and kidney function and thyroid hormone levels are checked at the start and regularly during treatment, because these organs can be affected before symptoms appear. Whether nivolumab is working is judged mainly by periodic scans, along with symptoms and examinations. Response differs widely: in some people the cancer shrinks or stops growing, while others see little effect. Occasionally a tumor looks larger on an early scan and then shrinks; this pattern, called pseudoprogression, was seen in about 6% of people on checkpoint inhibitors in one large analysis. Because true growth is far more common, the care team weighs repeat scans against symptoms before deciding whether to continue. After treatment ends, follow-up continues. Immune side effects can still begin months later, so any new symptom after the last dose is worth reporting and mentioning that nivolumab was given. Hormone problems such as an underactive thyroid may need lifelong replacement medicine.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Opdivo (Nivolumab), what you've noticed, or ask the community a question.